Pretreatment Characteristics of 256 ALL Patients by Cytogenetic Risk Group
| Characteristics . | Risk Group . | Total . | ||
|---|---|---|---|---|
| Unfavorable . | Miscellaneous . | Normal . | ||
| No. of patients | 100 | 77 | 79 | 256 |
| Age (yr) | ||||
| Median (range) | 43 (16-78)3-150 | 27 (16-80) | 30 (16-78) | 33 (16-80) |
| <30 | 28 (28%) | 43 (56%) | 38 (48%) | 109 (43%) |
| 30-59 | 49 (49%) | 26 (34%) | 30 (38%) | 105 (41%) |
| ≥60 | 23 (23%) | 8 (10%) | 11 (14%) | 42 (16%) |
| Sex | ||||
| Males | 52 (52%)3-151 | 48 (62%) | 55 (70%) | 155 (61%) |
| Females | 48 (48%) | 29 (38%) | 24 (30%) | 101 (39%) |
| Mediastinal mass (n = 252): present | 1 (1%)3-152 | 14 (18%) | 8 (10%) | 23 (9%) |
| Splenomegaly (n = 249): present | 16 (19%) | 35 (45%)3-151 | 22 (29%) | 75 (30%) |
| Lymphadenopathy (n = 247): present | 29 (30%) | 47 (63%)3-152 | 29 (38%) | 105 (43%) |
| Median WBC count (×103; n = 255) | 33.03-150 | 18.8 | 9.9 | 19.3 |
| Range | (1.0-392) | (0.7-326) | (0.7-411) | (0.7-411) |
| ≥30.0 | 53 (53%) | 27 (36%) | 20 (25%) | 100 (39%) |
| Median platelet count (×103; n = 255) | 56.03-150 | 67.0 | 82.0 | 61.0 |
| Range | (12-342) | (4-400) | (16-763) | (4-763) |
| Immunophenotype by uniparameter flow cytometry (n = 105) | ||||
| B | 20 (57%)3-150 | 16 (44%) | 9 (26%) | 45 (43%) |
| BMy | 9 (26%) | 3 (8%) | 10 (29%) | 22 (21%) |
| T | 2 (6%) | 12 (33%) | 10 (29%) | 24 (23%) |
| TMy | 0 | 3 (8%) | 3 (9%) | 6 (6%) |
| Other | 4 (11%) | 2 (6%) | 2 (6%) | 8 (8%) |
| Immunophenotype by multiparameter flow cytometry (n = 116) | ||||
| B | 34 (71%)3-150 | 20 (57%) | 15 (45%) | 69 (59%) |
| BMy | 12 (25%) | 5 (14%) | 6 (18%) | 23 (20%) |
| T | 0 | 4 (11%) | 10 (30%) | 14 (12%) |
| TMy | 0 | 3 (9%) | 1 (3%) | 4 (3%) |
| Other | 2 (4%) | 3 (9%) | 1 (3%) | 6 (5%) |
| Treatment protocols | ||||
| 8011, 8411, 8513 | 22 (22%) | 20 (26%) | 25 (32%) | 67 (26%) |
| 8811, 9111, 9311 | 78 (78%) | 57 (74%) | 54 (68%) | 189 (74%) |
| Characteristics . | Risk Group . | Total . | ||
|---|---|---|---|---|
| Unfavorable . | Miscellaneous . | Normal . | ||
| No. of patients | 100 | 77 | 79 | 256 |
| Age (yr) | ||||
| Median (range) | 43 (16-78)3-150 | 27 (16-80) | 30 (16-78) | 33 (16-80) |
| <30 | 28 (28%) | 43 (56%) | 38 (48%) | 109 (43%) |
| 30-59 | 49 (49%) | 26 (34%) | 30 (38%) | 105 (41%) |
| ≥60 | 23 (23%) | 8 (10%) | 11 (14%) | 42 (16%) |
| Sex | ||||
| Males | 52 (52%)3-151 | 48 (62%) | 55 (70%) | 155 (61%) |
| Females | 48 (48%) | 29 (38%) | 24 (30%) | 101 (39%) |
| Mediastinal mass (n = 252): present | 1 (1%)3-152 | 14 (18%) | 8 (10%) | 23 (9%) |
| Splenomegaly (n = 249): present | 16 (19%) | 35 (45%)3-151 | 22 (29%) | 75 (30%) |
| Lymphadenopathy (n = 247): present | 29 (30%) | 47 (63%)3-152 | 29 (38%) | 105 (43%) |
| Median WBC count (×103; n = 255) | 33.03-150 | 18.8 | 9.9 | 19.3 |
| Range | (1.0-392) | (0.7-326) | (0.7-411) | (0.7-411) |
| ≥30.0 | 53 (53%) | 27 (36%) | 20 (25%) | 100 (39%) |
| Median platelet count (×103; n = 255) | 56.03-150 | 67.0 | 82.0 | 61.0 |
| Range | (12-342) | (4-400) | (16-763) | (4-763) |
| Immunophenotype by uniparameter flow cytometry (n = 105) | ||||
| B | 20 (57%)3-150 | 16 (44%) | 9 (26%) | 45 (43%) |
| BMy | 9 (26%) | 3 (8%) | 10 (29%) | 22 (21%) |
| T | 2 (6%) | 12 (33%) | 10 (29%) | 24 (23%) |
| TMy | 0 | 3 (8%) | 3 (9%) | 6 (6%) |
| Other | 4 (11%) | 2 (6%) | 2 (6%) | 8 (8%) |
| Immunophenotype by multiparameter flow cytometry (n = 116) | ||||
| B | 34 (71%)3-150 | 20 (57%) | 15 (45%) | 69 (59%) |
| BMy | 12 (25%) | 5 (14%) | 6 (18%) | 23 (20%) |
| T | 0 | 4 (11%) | 10 (30%) | 14 (12%) |
| TMy | 0 | 3 (9%) | 1 (3%) | 4 (3%) |
| Other | 2 (4%) | 3 (9%) | 1 (3%) | 6 (5%) |
| Treatment protocols | ||||
| 8011, 8411, 8513 | 22 (22%) | 20 (26%) | 25 (32%) | 67 (26%) |
| 8811, 9111, 9311 | 78 (78%) | 57 (74%) | 54 (68%) | 189 (74%) |
Presence of central nervous system disease, hepatomegaly, and the French-American-British classification did not differ between the groups. P values represent difference from the normal karyotype group (for immunophenotype the comparison is for B-lineagev T-lineage).
Abbreviations: ND, not done; NE, not evaluable.
P < .005.
.01 < P < .05.
.005 < P < .01.